"Crinetics Pharmaceuticals will present six abstracts at the Endocrine Society's Annual Meeting, ENDO 2026. Presentations include long-term safety and efficacy data for PALSONIFY (paltusotine) in acromegaly. New data for the investigational candidate atumelnant in congenital adrenal hyperplasia and Cushing’s syndrome will be shared."